Timothy Coetzee
Overview
Explore the profile of Timothy Coetzee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
3045
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bebo Jr B, Banwell B, Whitacre C, Coetzee T, Dalgas U, De Jager P, et al.
Mult Scler
. 2024 Aug;
30(10):1242-1251.
PMID: 39212108
Background: Multiple sclerosis is a chronic immune-mediated disease of the central nervous system affecting nearly 3 million people worldwide. Although much progress has been made in the understanding and treatment...
2.
Zaratin P, Samadzadeh S, Seferoglu M, Ricigliano V, Silva J, Tunc A, et al.
Front Neurol
. 2024 Jul;
15:1407257.
PMID: 38974689
Significant advancements have been achieved in delineating the progress of the Global PROMS (PROMS) Initiative. The PROMS Initiative, a collaborative endeavor by the European Charcot Foundation and the Multiple Sclerosis...
3.
Thompson A, Moccia M, Amato M, Calabresi P, Finlayson M, Hawton A, et al.
Mult Scler
. 2023 Sep;
29(11-12):1363-1372.
PMID: 37691493
Background And Objectives: The current clinical course descriptors of multiple sclerosis (MS) include a combination of clinical and magnetic resonance imaging (MRI) features. Recently there has been a growing call...
4.
Jakimovski D, Kavak K, Zakalik K, Coetzee T, Gottesman M, Coyle P, et al.
Mult Scler
. 2022 Dec;
29(6):753-756.
PMID: 36545928
Judicious multiple sclerosis (MS) diagnosis and early start of disease modifying therapy significantly improves long-term disability outcomes in persons with MS (pwMS). Retrospective analysis based on 25-year New York State...
5.
Kuhlmann T, Moccia M, Coetzee T, Cohen J, Correale J, Graves J, et al.
Lancet Neurol
. 2022 Nov;
22(1):78-88.
PMID: 36410373
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors-relapsing-remitting, secondary progressive, and primary progressive-for patient care, research, and regulatory approval of medications. Accumulating evidence suggests that the clinical course...
6.
Zaratin P, Banwell B, Coetzee T, Comi G, Feinstein A, Hyde R, et al.
Mult Scler J Exp Transl Clin
. 2022 May;
8(2):20552173221099181.
PMID: 35530174
Background: The COVID-19 pandemic has reinforced the importance of research for the health of our society and highlighted the need for stakeholders of the health research and care continuum to...
7.
Zaratin P, Vermersch P, Amato M, Brichetto G, Coetzee T, Cutter G, et al.
Mult Scler Relat Disord
. 2022 Apr;
61:103757.
PMID: 35367873
On 12 September 2019, the global Patient Reported Outcome for Multiple Sclerosis (PROMS) Initiative was launched at the 35th Congress of the European Committee for Treatment and Research in Multiple...
8.
Bebo Jr B, Allegretta M, Landsman D, Zackowski K, Brabazon F, Kostich W, et al.
Mult Scler
. 2022 Mar;
28(3):331-345.
PMID: 35236198
Background: Multiple Sclerosis (MS) is a growing global health challenge affecting nearly 3 million people. Progress has been made in the understanding and treatment of MS over the last several...
9.
Thompson A, Carroll W, Ciccarelli O, Comi G, Cross A, Donnelly A, et al.
Mult Scler
. 2021 Dec;
28(1):16-28.
PMID: 34850641
Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have...
10.
Coetzee T, Price Ball M, Boutin M, Bronson A, Dexter D, English R, et al.
J Particip Med
. 2021 Jul;
13(2):e31371.
PMID: 34255670
[This corrects the article DOI: 10.2196/23011.].